Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

late the production of IL-1, which causes an inflammatory response in the joints and surrounding tissues.

Rilonacept, also known as IL-1 Trap, is an agent that inhibits IL-1.  It was designed using the same proprietary Trap technology used to develop Regeneron's other product candidates, VEGF Trap and VEGF Trap-Eye.  Specifically, rilonacept is designed to attach to and neutralize IL-1 in the blood stream before the IL-1 can attach to cell-surface receptors and generate signals that can trigger disease activity in body tissue.  Once attached to rilonacept, IL-1 cannot bind to the cell-surface receptors and is eventually eliminated from the body.

Important Information About ARCALYSTRilonacept, marketed as ARCALYST, is currently indicated in the U.S. for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.  Rilonacept is also approved, but not marketed, in the E.U. for the same patient population.  The safety and efficacy of ARCALYST® (rilonacept) in the gout setting have not been evaluated by the U.S. Food and Drug Administration.  ARCALYST is not approved for use in gout.

IL-1 blockade may interfere with immune response to infections.  Serious, life-threatening infections have been reported in patients taking rilonacept.  Rilonacept should be discontinued if a patient develops a serious infection.  Taking rilonacept with tumor necrosis factor inhibitors is not recommended because this may increase the risk of serious infections.  Treatment with rilonacept should not be initiated in patients with active or chronic infections.  Patients should not receive a live vaccine while taking rilonacept.  It is recommended that patients receive all recommended vaccinations prior to initiation of treatment with rilonac
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 1 Graymark Healthcare , Inc. (Nasdaq: ... which Walgreen Co. will acquire substantially all of the ... Graymark Healthcare . Graymark expects to realize a total ... AR, expenses and proceeds from the liquidation of remaining ...
... Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company 2Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 2French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 4French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 5French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 6French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 7
(Date:4/22/2014)... high school sport in the United States with 1 ... in the Center for Injury Research and Policy at ... describe the occurrence and distribution patterns of basketball-related injuries ... training setting among adolescents and teens. , The study, ... , examined data relating to adolescents 13-19 years of ...
(Date:4/22/2014)... decades researchers have characterized a set of clock genes ... all types of species, from flies to humans. Over ... surmise there are more. A team from the Perelman ... if big-data approaches could find them. , To ... PhD, professor of Pharmacology and first author Ron Anafi, ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2
... WOODS HOLE, MASummer on Cape Cod is synonymous with ... scientists at the MBL (Marine Biological Laboratory). For more ... each summer from around the world to immerse themselves ... of marine organisms available for study and the wealth ...
... like children brings out more resistance, study found , , ... often become upset and even act out when nurses ... them, a new,study shows. , Researchers who taped the ... Alzheimer,s found that the residents often became more agitated ...
... Counseling LLC launches new website offering convenient http://www.terrimilen.com [Online ... in the comfort of their own home or office. , ... ... effort to provide clients with an alternative to traditional therapy which ...
... better quality of life , , SATURDAY, July 26 (HealthDay News) ... on the body may one day be to dialysis patients ... automated, wearable artificial kidney (AWAK) works better than conventional dialysis, ... Clinical and Experimental Nephrology . , "What,s really new about ...
... & Olsen LLP has filed a,class action lawsuit against ... and certain of its officers in the U.S. District,Court ... all persons or,entities who purchased the common stock ArthroCare ... Stock Purchaser Class Period") and all,persons or entities who ...
... of Phoenix employees at 62 campuses, 43 affiliated sites open ... cupboards, hearts to help feed nation,s hungry, ... the,nation,s hungry as employees at University of Phoenix, 62 campuses, ... food items and monetary donations to provide more,than 68,000 meals. ...
Cached Medicine News:Health News:LabBits: A media tip sheet from the MBL in Woods Hole 2Health News:LabBits: A media tip sheet from the MBL in Woods Hole 3Health News:LabBits: A media tip sheet from the MBL in Woods Hole 4Health News:Alzheimer's Patients React Poorly to 'Elderspeak' 2Health News:Alzheimer's Patients React Poorly to 'Elderspeak' 3Health News:Online Counseling and Life Coaching Practice Launches New Website 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Hunger Is Happening National Food Drive a Huge Success -- Donations Will Serve 68,000 Meals 2
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Wire Reinforced Endotracheal Tube Kits (silicone) ... individually and includes a SidePort™ AutoControl™ ... and 15 mm ISO connector., ... safety by helping to ensure an ...
... uncuffed endotracheal tubes are available ... in standard or precut lengths., ... pediatric uncuffed endotracheal tubes are ... with a radiopaque blue line ...
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Medicine Products: